Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

Comment: Immunotherapy plus chemotherapy in bladder cancer

Comment: PARP inhibitors for advanced prostate cancer

PARP inhibitor olaparib slows progression of advanced prostate cancer

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy

Ovarian highlights from ESMO 2019

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC